Zobrazeno 1 - 10
of 157
pro vyhledávání: '"David W. Boulton"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 11, Pp 1870-1880 (2024)
Abstract Despite the benefits of breastfeeding, lactating mothers who take prescribed medications may discontinue breastfeeding due to concerns associated with infant drug exposure in breastmilk. Consolidating the current knowledge of drug transport
Externí odkaz:
https://doaj.org/article/c5fcf197f63a4f0a9d2e92fe10b1710d
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 2, Pp 296-307 (2024)
Abstract Potassium (K+) is the main intracellular cation in the body. Elevated K+ levels (hyperkalemia) increase the risk of life‐threatening arrhythmias and sudden cardiac death. However, the details of K+ homeostasis and the effects of orally adm
Externí odkaz:
https://doaj.org/article/13e156a6bf924f898f09a9f1f969e99c
Autor:
Hongtao Yu, Peter Greasley, Hiddo Lambers-Heerspink, David W. Boulton, Bengt Hamrén, K. Melissa Hallow
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Endothelin-1 (ET-1) is a potent vasoconstrictor with strong anti-natriuretic and anti-diuretic effects. While many experimental studies have elucidated the mechanisms of ET-1 through its two receptors, ETA and ETB, the complexity of responses and som
Externí odkaz:
https://doaj.org/article/6f343abb9e014ce281dd38d5994d3258
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Background and objectivePublished works have discussed the pharmacokinetic interactions of drugs with pregnancy, but none comprehensively identify all the approved United States Food and Drug Administration (FDA) and European Medicines Administration
Externí odkaz:
https://doaj.org/article/1ccdc4d5c0654780970b5c24d95953ea
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: Dapagliflozin-induced improvement of glycemic control in patients with inadequately controlled type 1 diabetes (T1D) is complicated by the delicate balance between blood glucose and exogenous insulin. In this work, we developed a semi-m
Externí odkaz:
https://doaj.org/article/b7bcb824b744490195e37975eee3fdf2
Publikováno v:
Pharmaceutics, Vol 15, Iss 11, p 2624 (2023)
The purpose of this literature review is to comprehensively summarize changes in the expression of phase II drug-metabolizing enzymes and drug transporters in both the pregnant woman and the placenta. Using PubMed®, a systematic search was conducted
Externí odkaz:
https://doaj.org/article/a96c35c23eea4e178c7fec153ecf8106
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 2, Pp 108-118 (2021)
This analysis reports a quantitative modeling and simulation approach for oral dapagliflozin, a primarily uridine diphosphate‐glucuronosyltransferase (UGT)–metabolized human sodium‐glucose cotransporter 2 selective inhibitor. A mechanistic dapa
Externí odkaz:
https://doaj.org/article/04577c1c615147d1a35e59ffeccf1fba
Autor:
Victor Sokolov, Tatiana Yakovleva, Lulu Chu, Weifeng Tang, Peter J. Greasley, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W. Boulton, Robert C. Penland
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 4, Pp 222-229 (2020)
The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative
Externí odkaz:
https://doaj.org/article/4f5804238a5a4ff3b4cb5e7de0343122
Autor:
Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz, Rury R. Holman
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-12 (2019)
Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence
Externí odkaz:
https://doaj.org/article/3fa36748485b487cb3cfa5fcb2b66bfd
Autor:
Gabriel Helmlinger, Victor Sokolov, Kirill Peskov, Karen M. Hallow, Yuri Kosinsky, Veronika Voronova, Lulu Chu, Tatiana Yakovleva, Ivan Azarov, Daniel Kaschek, Artem Dolgun, Henning Schmidt, David W. Boulton, Robert C. Penland
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 6, Pp 380-395 (2019)
Quantitative systems pharmacology (QSP), a mechanistically oriented form of drug and disease modeling, seeks to address a diverse set of problems in the discovery and development of therapies. These problems bring a considerable amount of variability
Externí odkaz:
https://doaj.org/article/0bc86cacff10421bbe8ac64b3a5e719b